Access Statistics for Tomas Philipson

Author contact details at EconPapers.

Working Paper File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Adjusting Measures of Economic Output for Health: Is the Business Cycle Countercyclical? 0 0 0 0 0 0 1 2
Adjusting National Accounting for Health: Is the Business Cycle Countercyclical? 0 0 0 62 0 0 0 90
Aging and the Growth of Long-Term Care 0 0 0 30 0 0 4 144
Aging and the Growth of Long-Term Care 0 0 0 243 0 0 3 1,293
An Economic Evaluation of the War on Cancer 0 0 0 97 1 1 3 361
An Empirical Examination of Information Barriers to Trade in Insurance 0 0 0 0 0 0 1 1,047
An Empirical Examination of Information Barriers to Trade in Insurance 0 0 0 420 1 2 5 2,630
Antitrust and the Not-For-Profit Sector 0 0 0 321 0 1 1 1,048
Antitrust in the Not-For-Profit Sector 0 0 0 173 0 0 0 780
Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process 0 0 0 86 0 0 2 507
Assessing the Safety and Efficacy of the FDA: The Case of the Prescription Drug User Fee Acts 0 0 0 0 0 0 1 4
Assessing the Safety and Efficacy of the FDA: The Case of the Prescription Drug User Fee Acts 0 0 0 77 0 0 0 258
Can Medical Progress be Sustained? Implications of the Link Between Development and Output Markets 0 0 0 37 0 0 0 114
Can Medical Progress be Sustained? Implications of the Link Between Development and Output Markets 0 0 0 0 0 0 1 1
Consumption vs. Production of Insurance 0 0 0 108 0 0 2 765
Cost-Benefit Analysis of the FDA: The Case of the Prescription Drug User Fee Acts 0 0 0 1 0 0 3 5
Data MArkets and OPtimal Sample Size Determination 0 0 0 0 1 1 3 2,835
Death, Tetanus and Aerobics: The Evaluation of Disease-Specific Health Interventions 0 0 0 49 0 0 2 457
Death, tetanus, and aerobics: The evaluation of disease-specific health interventions 0 0 0 11 0 0 1 215
Disease Complementarities and the Evaluation of Public Health Interventions 0 0 0 124 0 0 0 902
Disease Eradication: Private vs. Public Vaccination 0 0 0 0 1 2 3 568
Economic Analysis of Risk and Uncertainty induced by Health Shocks: A Review and Extension 0 0 0 48 0 0 5 129
Economic Epidemiology and Infectious Diseases 0 0 5 918 1 1 12 2,742
Endogenous Cost-Effectiveness Analysis in Health Care Technology Adoption 0 0 0 57 0 1 2 303
Estimating the Extent of Trade Under Incomplete Information: The Case of HIV 0 0 0 0 0 0 0 133
External Treatment Effects and Program Implementation Bias 0 0 0 76 0 0 0 543
External Treatment Effects and Program Implementation Bias 0 0 0 15 0 0 0 106
Financial Health Economics 1 1 1 145 1 2 6 348
Health Care Adherence and Personalized Medicine 0 0 0 66 0 0 2 71
Health Care, Technological Change, and Altruistic Consumption Externalities 0 0 0 48 0 0 2 372
Health investment complementarities under competing risks 0 0 0 213 0 0 2 1,178
How Does Technological Change Affect Quality-Adjusted Prices in Health Care? Systematic Evidence from Thousands of Innovations 0 0 0 91 0 0 3 67
Integrated Insurance Design in the Presence of Multiple Medical Technologies 0 0 0 23 0 0 1 170
Intellectual Property & External Consumption Effects: Generalizations From Health Care Markets 0 0 0 0 0 0 2 4
Intellectual Property & External Consumption Effects: Generalizations From Health Care Markets 0 0 0 1 0 0 2 3
Intellectual Property & External Consumption Effects: Generalizations from Pharmaceutical Markets 0 0 0 151 0 0 1 559
Intellectual Property and Marketing 0 0 0 91 0 2 6 392
Intellectual Property and Marketing 0 0 0 0 0 1 4 6
International Health Economics 0 0 0 47 0 0 2 82
International Health Economics 0 0 0 0 0 0 2 3
Is Health Care Technology Over-Approved? A Meta-Analysis of Revealed Preference 0 0 0 0 0 1 1 180
Is the Food and Drug Administration Safe and Effective? 0 0 0 1 1 1 2 4
Is the Food and Drug Administration Safe and Effective? 0 0 0 78 0 1 1 273
Is the Obesity Epidemic a Public Health Problem? A Decade of Research on the Economics of Obesity 0 0 0 406 0 1 2 1,261
Merit Motives & Government Intervention: Public Finance in Reverse 0 0 0 123 0 0 1 625
Merit Motives and Government Intervention: Public Finance in Reverse 0 0 1 124 0 0 2 1,150
Merit Motives and Government Intervention: Public Finance in Reverse 0 0 0 203 0 1 3 862
Mortality Contingent Claims, Health Care, and Social Insurance 0 1 1 162 0 1 2 598
Mortality Contingent Claims, Health Care, and Social Insurance 0 0 0 2 0 0 3 1,172
Nonprofit Production 0 0 0 0 0 0 1 196
Nonprofit Production and Competition 0 1 1 300 0 2 2 1,255
Observational Agency and Supply-Side Econometrics 0 0 0 28 0 0 0 389
Pricing and R&D with Related Margins 0 0 0 0 0 0 1 562
Public Liabilities and Health Care Policy 0 0 0 32 0 0 3 100
Rational Epidemics and their Public Control 0 0 0 0 0 1 7 631
Self-Interested Treatment Evaluation in Experiments 0 0 0 0 0 0 0 109
Sharing R&D Risk in Healthcare via FDA Hedges 0 0 0 28 0 0 3 93
Surplus Appropriation from R&D and Health Care Technology Assessment Procedures 0 0 0 72 0 1 3 378
Surplus Appropriation from R&D and Health Care Technology Assessment Procedures 0 0 0 105 0 1 2 662
Terminal Care and The Value of Life Near Its End 1 1 2 210 1 2 9 695
The Dual Effects of Intellectual Property Regulations: Within- and Between- Patent Competition in the US Pharmaceuticals Industry 0 0 0 283 0 0 1 947
The Dual Effects of Intellectual Property Regulations: Within- and Between-Patent Competition in The US Pharmaceuticals Industry 0 0 0 0 0 0 3 5
The Dual Effects of Intellectual Property Regulations: Within- and Between-Patent Competition in the US 0 0 0 37 0 0 0 135
The Effects of Product Liability Exemption in the Presence of the FDA 0 0 0 19 0 1 2 196
The Future of Old-Age Longevity: Competitive Pricing of Morality Contingent Claims 0 0 0 0 0 0 1 997
The Future of Old-Age Longevity: Competitive Pricing of Mortality Contingent Claims 0 0 0 68 0 0 1 345
The Growth of Obesity and Technological Change: A Theoretical and Empirical Examination 0 0 0 492 0 0 2 1,603
The Growth of Obesity and Technological Change: A Theoretical and Empirical Examination 0 0 0 0 0 0 3 5
The Growth of Obesity and Technological Change: A Theoretical and Empirical Examination 0 0 1 89 0 1 6 372
The Impact of Comparative Effectiveness Research on Health and Health Care Spending 0 0 0 57 1 1 1 229
The Long-Run Growth in Obesity as a Function of Technological Change 0 0 1 594 0 0 3 2,276
The Long-Run Growth in Obesity as a Function of Technological Change 0 0 0 89 0 0 1 343
The Private Demand for Information and the Effects of Public Testing Programs: The Case of HIV 0 0 0 0 1 1 2 457
The Quantity and Quality of Life and the Evolution of World Inequality 0 0 6 919 0 0 11 2,694
The Rise in Old Age Longevity and the Market for Long-Term Care 0 0 0 234 0 1 2 1,776
The Rise in Old Age Longevity and the Market for Long-Term Care 0 0 1 3 0 0 2 771
The Value of Life Near its End and Terminal Care 1 1 2 230 1 2 3 447
The Value of Life Near its End and Terminal Care 0 0 0 267 2 4 19 761
The Value of Life in General Equilibrium 0 0 0 92 0 0 4 351
Who Benefits from New Medical Technologies? Estimates of Consumer and Producer Surpluses for HIV/AIDS Drugs 0 0 0 136 0 0 1 600
Will the AIDS Epidemic be Self-Limiting? Evidence on the Responsiveness of the Demand for Condoms to the Prevalence of AIDS 0 0 0 40 1 1 20 308
Will the AIDS Epidemic be Self-Limiting? Evidence on the Responsiveness of the Demand for Condoms to the Prevalence of AIDS 0 0 0 1 1 1 3 264
Total Working Papers 3 5 22 9,353 15 40 229 48,314


Journal Article File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
A Cost-Benefit Analysis of Using Evidence of Effectiveness in Terms of Progression Free Survival in Making Reimbursement Decisions on New Cancer Therapies 0 0 1 57 1 1 3 216
A Reexamination of the Costs of Medical R&D Regulation 0 0 0 13 1 1 5 68
A Theoretical and Empirical Investigation of the Effects of Public Health Subsidies for STD Testing 0 0 0 135 0 0 3 452
Altruism and Innovation in Health Care 0 1 1 21 0 2 2 138
An Empirical Examination of Information Barriers to Trade in Insurance 0 0 0 222 0 0 1 950
An economic evaluation of the war on cancer 0 0 4 108 0 0 9 580
An empirical examination of the implications of assortative matching on the incidence of HIV 0 0 0 39 0 0 1 86
Antitrust in the Not-for-Profit Sector 0 1 1 114 0 3 4 455
Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process 0 0 0 29 0 2 4 304
Can Oral Nutritional Supplements Improve Medicare Patient Outcomes in the Hospital? 0 0 0 35 0 0 1 179
Commentary 0 0 0 2 0 0 0 8
Commentary 0 0 0 3 0 0 0 26
Commentary 0 0 0 2 0 0 1 13
Cost-benefit analysis of the FDA: The case of the prescription drug user fee acts 0 0 4 143 1 4 21 721
Cost-effectiveness analysis and innovation 0 1 2 112 1 3 6 419
Data Markets and the Production of Surveys 0 0 0 22 0 1 5 103
Data Markets, Missing Data, and Incentive Pay 0 0 0 0 0 0 2 182
Defining Value: The Need for a Longer, Broader View 0 0 0 15 0 0 1 59
Desegregation and Social Monopoly Pricing 0 0 0 2 0 0 1 5
Disease Eradication: Private versus Public Vaccination 2 2 7 414 3 5 19 1,042
Does Intellectual Property Restrict Output? An Analysis of Pharmaceutical Markets 0 0 0 40 0 0 2 169
Dynamic information release 0 0 0 3 0 0 0 12
Endogenous cost-effectiveness analysis and health care technology adoption 0 0 0 18 0 1 3 109
Equilibrium and Efficiency in an Organized Vote Market 0 0 0 0 1 1 2 237
Erratum: Valuing health technologies at NICE: recommendations for improved incorporation of treatment value in HTA 0 0 0 3 0 0 0 20
Evaluating an Argument for Affirmative Action 0 0 0 3 0 0 2 12
External Costs of Risky Health Behaviors Associated with Leading Actual Causes of Death in the U.S.: A Review of the Evidence and Implications for Future Research 0 0 0 0 0 0 2 5
Financial Health Economics 1 1 4 47 3 3 12 183
Geographic Variation in Health Care: The Role of Private Markets 0 0 0 75 1 1 5 420
HETEROGENEITY IN ACTION: THE ROLE OF PASSIVE PERSONALIZATION IN COMPARATIVE EFFECTIVENESS RESEARCH 0 0 0 2 0 0 0 24
How Does Technological Change Affect Quality-Adjusted Prices in Health Care? Systematic Evidence from Thousands of Innovations 1 1 2 9 2 3 6 55
How Does Technological Change Affect Quality-Adjusted Prices in Health Care? Systematic Evidence from Thousands of Innovations 1 1 1 14 3 3 7 46
Integrated Insurance Design in the Presence of Multiple Medical Technologies 0 0 0 23 0 0 0 245
Is the Food And Drug Administration Safe And Effective? 0 0 0 21 0 2 8 324
Is the Obesity Epidemic a Public Health Problem? A Review of Zoltan J. Acs and Alan Lyles's Obesity, Business and Public Policy 0 0 1 27 0 0 5 388
Labor Markets in Statistics: The Subject Supply Effect in Medical R&D 0 0 0 2 0 1 2 27
Labor Supply and Weight 0 1 3 50 0 1 4 137
Longevity Complementarities under Competing Risks 0 0 0 164 0 1 6 550
Managed Care and the Quality of Health Care: A Misguided Debate? 0 0 0 0 0 0 0 231
Measurement errors: A principal investigator-agent approach 0 0 0 38 0 0 0 124
Multiple-output agency incentives in data production: experimental evidence 0 0 0 12 0 0 0 57
Old-Age Longevity and Mortality-Contingent Claims 0 1 2 318 0 1 7 844
Pricing and R&D When Consumption Affects Longevity 0 0 0 0 0 0 0 199
Private Vaccination and Public Health: An Empirical Examination for U.S. Measles 0 1 1 44 0 1 2 166
Public Financing and the Market for Long-Term Care 0 0 0 24 0 0 0 99
Public Spending on AIDS Education: An Economic Analysis 0 0 0 5 0 0 0 244
Quantifying Gains in the War on Cancer Due to Improved Treatment and Earlier Detection 0 0 2 41 1 2 10 155
Quantifying the Value of Personalized Medicines: Evidence from COX-2 Inhibitors 0 0 0 10 0 0 0 68
RESPONSE TO EPSTEIN'S COMMENT ON “HETEROGENEITY IN ACTION” 0 0 0 1 0 0 1 18
Rational Epidemics and Their Public Control 0 0 0 1 1 4 13 682
Sharing R&D Risk in Healthcare via FDA Hedges 0 0 0 3 0 0 4 9
Should Global Health be Tailored Toward the Rich? Altruism and Efficient R&D for Neglected Diseases 0 0 0 7 0 0 0 40
Social Welfare and Measurement of Segregation 0 0 1 71 0 0 1 143
Subject Evaluation in Social Experiments 0 0 0 0 0 0 0 369
The Contributions of Improved Therapy and Earlier Detection to Cancer Survival Gains, 1988-2000 0 0 1 72 0 0 3 296
The Dual Effects of Intellectual Property Regulations: Within- and Between-Patent Competition in the U.S. Pharmaceuticals Industry 0 0 1 31 0 0 5 284
The Economic Epidemiology of Crime 0 0 4 46 1 1 6 1,095
The Impact of Public Testing for Human Immunodeficiency Virus 0 0 0 35 0 0 2 99
The Option Value of Innovation 0 0 0 45 0 0 0 214
The Quantity and Quality of Life and the Evolution of World Inequality 0 0 7 715 0 3 37 2,362
The Regulation of Medical Innovation and Pharmaceutical Markets 0 0 0 10 1 1 1 25
The Responsiveness of the Demand for Condoms to the Local Prevalence of AIDS 0 0 1 31 0 0 2 165
The Rise in Old-Age Longevity and the Market for Long-Term Care 0 0 0 106 0 1 4 444
The Value of Diagnostic Testing in Personalized Medicine 0 0 0 60 0 5 6 224
The evaluation of new health care technology: The labor economics of statistics 0 0 0 70 0 0 0 356
The growth of obesity and technological change 0 0 0 32 0 0 5 136
The impact of comparative effectiveness research on health and health care spending 0 0 0 35 0 1 2 275
The institute of medicine report on the FDA: where is the science? 0 0 0 26 0 0 1 139
The nonprofit sector and industry performance 0 1 1 256 0 3 8 707
The welfare loss of disease and the theory of taxation 0 0 1 54 1 1 4 140
The world‐wide growth in obesity: an economic research agenda 0 0 0 9 0 1 3 639
Valuing health technologies at nice: recommendations for improved incorporation of treatment value in HTA 0 0 0 26 0 0 0 100
Welfare-Enhancing Technological Change and the Growth of Obesity 0 0 1 152 0 0 4 428
Who Benefits from New Medical Technologies? Estimates of Consumer and Producer Surpluses for HIV/AIDS Drugs 1 2 4 115 2 6 24 613
`Me-Too' Innovation in Pharmaceutical Markets 1 1 1 78 1 2 3 293
`RATIONAL CHOICE, PUBLIC POLICY AND AIDS' 0 0 0 0 0 0 0 2
Total Journal Articles 7 15 59 4,568 25 72 313 21,453


Book File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Health and Wealth Disparities in the United States 0 1 1 6 0 1 1 34
Total Books 0 1 1 6 0 1 1 34


Chapter File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
"Me-Too" Innovation in Pharmaceutical Markets 0 0 0 0 1 4 12 265
A direct test of the 'lemons' model: the market for used pickup trucks 0 0 4 14 0 0 9 64
Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process 0 0 0 0 0 1 1 137
Asymmetric Information and the Not-for-Profit Sector Does Its Output Sell a a Premium? 0 0 0 19 0 0 1 65
Economic epidemiology and infectious diseases 0 2 15 953 1 6 30 2,982
Economics of Obesity 0 0 0 37 1 1 4 99
Economics of Obesity 0 0 2 25 0 0 4 91
Medical Care Output and Productivity in the Nonprofit Sector 0 0 0 12 0 0 0 62
Public Financing and the Market for Long-Term Care 0 0 0 8 0 0 3 52
The Economic Value and Pricing of Personalized Medicine 0 0 0 27 0 1 2 77
The Effects of Product Liability Exemption in the Presence of the FDA 0 0 0 24 0 1 8 130
Theories of Firm Behavior in the Nonprofit Sector. A Synthesis and Empirical Evaluation 0 0 0 147 0 0 1 423
Total Chapters 0 2 21 1,266 3 14 75 4,447


Statistics updated 2025-07-04